Yuanquan A. Yang

Oncology

300 W 10th Ave
Columbus, OH 43210

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 55 publications

Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801).

Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 27, 2026

Multi-omic characterization of 14q deletion in renal clear cell carcinoma identifies EDNRB as a predictor of immunotherapy response.

Multi-omic characterization of 14q deletion in renal clear cell carcinoma identifies EDNRB as a predictor of immunotherapy response.

Journal: Journal for immunotherapy of cancer

Published: June 29, 2026

How the Ketogenic Diet Shapes the Microbiome to Influence Cancer Immunotherapy Outcomes: An Exploration of Clinical Trials and Their Results.

How the Ketogenic Diet Shapes the Microbiome to Influence Cancer Immunotherapy Outcomes: An Exploration of Clinical Trials and Their Results.

Journal: Nutrition and cancer

Published: May 04, 2026

CLO26-084: Prognostic Value of Sarcopenia in Patients With Metastatic NSCLC Receiving First-Line Immune Checkpoint Inhibitors.

CLO26-084: Prognostic Value of Sarcopenia in Patients With Metastatic NSCLC Receiving First-Line Immune Checkpoint Inhibitors.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 30, 2026

CLO26-084: Prognostic Value of Sarcopenia in Patients With Metastatic NSCLC Receiving First-Line Immune Checkpoint Inhibitors.

CLO26-084: Prognostic Value of Sarcopenia in Patients With Metastatic NSCLC Receiving First-Line Immune Checkpoint Inhibitors.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2026

Incidence of Germline Genetic Variants in Patients with a Urinary Tract Cancer and Association with Outcomes.

Incidence of Germline Genetic Variants in Patients with a Urinary Tract Cancer and Association with Outcomes.

Journal: European urology oncology

Published: March 27, 2026

The temporal dynamics of the immune response to neoadjuvant androgen deprivation therapy suggests a window-of-opportunity for checkpoint inhibitor therapy in prostate cancer.

The temporal dynamics of the immune response to neoadjuvant androgen deprivation therapy suggests a window-of-opportunity for checkpoint inhibitor therapy in prostate cancer.

Journal: medRxiv : the preprint server for health sciences

Published: February 06, 2026

Association between obesity, sex, medical comorbidities, and survival in cancer patients treated with immune checkpoint inhibitors.

Association between obesity, sex, medical comorbidities, and survival in cancer patients treated with immune checkpoint inhibitors.

Journal: Journal of Cancer

Published: December 16, 2025

Development of Patient-Derived Neuroprogenitor Cells (hNPCs), Neurons and Astrocytes to Explore the Etiology of Guam Parkinsonism-Dementia Complex (PDC).

Development of Patient-Derived Neuroprogenitor Cells (hNPCs), Neurons and Astrocytes to Explore the Etiology of Guam Parkinsonism-Dementia Complex (PDC).

Journal: bioRxiv : the preprint server for biology

Published: December 03, 2025

An atypical presentation of immune checkpoint inhibitor associated myositis with normal creatine kinase: a case report.

An atypical presentation of immune checkpoint inhibitor associated myositis with normal creatine kinase: a case report.

Journal: Frontiers in immunology

Published: July 09, 2025

The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404).

The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404).

Journal: Cancer research communications

Published: June 06, 2025

Race and Outcomes to [177Lu]Lu-PSMA-617 in Advanced Prostate Cancer.

Race and Outcomes to [177Lu]Lu-PSMA-617 in Advanced Prostate Cancer.

Journal: Cancers

Published: April 29, 2025

Showing 1-12 of 55

Last Updated: 09/26/2026